• Sanofi SA, of Paris, and Bristol-Myers Squibb Co. (BMS), of New York, restructured their long-term alliance following the loss of exclusivity of Plavix (clopidogrel bisulfate) and Avapro (irbesartan)/Avalide (irbesartan-hydrochlorothiazide) in most markets.